A Phase II Study of Olaparib in Patients with Advanced Biliary Tract Cancer


Full Title

A Phase II Study of Olaparib in Patients with Advanced Biliary Tract Cancer with Aberrant DNA Repair Gene Mutations


In this study, researchers are assessing the effectiveness of the drug olaparib to treat patients with advanced biliary tract cancer that contains a mutation in one or more genes involved in the repair of DNA damage in cancer cells. Olaparib is a type of medication called a PARP inhibitor. It blocks PARP proteins from repairing damage (including DNA damage) in cancer cells, which may cause cancer cells to die. 

Olaparib is used to treat some forms of cancer that have changes in their DNA repair genes; its use in this study is considered investigational. Olaparib is taken orally (by mouth).

Who Can Join

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have advanced biliary tract cancer that did not progress on platinum-based chemotherapy and has one or more mutations in DNA repair genes.
  • At least 4 weeks must pass between the completion of prior therapies and receipt of olaparib.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Wungki Park at 646-888-4543.




Phase II (phase 2)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID